{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:51:41Z","timestamp":1793224301618,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.esmoop.2022.100565","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T12:28:10Z","timestamp":1660912090000},"page":"100565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"X.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100565_bib1","article-title":"Resveratrol and cervical cancer: a new therapeutic option?","author":"Shafabakhsh","year":"2022","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.esmoop.2022.100565_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2022.100565_bib3","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.esmoop.2022.100565_bib4","first-page":"912","article-title":"[Epidemiological trend of cervical cancer]","volume":"43","author":"Li","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zh.i"},{"key":"10.1016\/j.esmoop.2022.100565_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GRF.0000000000000507","article-title":"Updates in cervical cancer treatment","volume":"63","author":"Hill","year":"2020","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.esmoop.2022.100565_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","article-title":"Cervical Cancer, Version 3. 2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Koh","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2022.100565_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial","volume":"19","author":"Tang","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CMAR.S35785","article-title":"Nedaplatin: a cisplatin derivative in cancer chemotherapy","volume":"5","author":"Shimada","year":"2013","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmoop.2022.100565_bib9","doi-asserted-by":"crossref","first-page":"798617","DOI":"10.3389\/fonc.2021.798617","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in patients with stage IIB-IVA cervical cancer: a randomized phase III trial","volume":"11","author":"He","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib10","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(15)00305-8","article-title":"Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial","volume":"16","author":"Shukuya","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-020-6592-2","article-title":"A\u00a0phase-II\/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB\/III esophageal squamous cell carcinoma","volume":"20","author":"Ni","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100565_bib12","first-page":"963159","article-title":"Nedaplatin: a radiosensitizing agent for patients with cervical cancer","volume":"2011","author":"Mabuchi","year":"2011","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.esmoop.2022.100565_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/IGC.0000000000001265","article-title":"Comparison of nedaplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients: a propensity score analysis","volume":"28","author":"Li","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.esmoop.2022.100565_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10147-016-0946-4","article-title":"Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study","volume":"21","author":"Kagabu","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib15","first-page":"8661","article-title":"Efficacy of concurrent single-agent chemotherapy using radiotherapy in patients with cervical cancer: a meta-analysis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.esmoop.2022.100565_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jrr\/rru101","article-title":"Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors","volume":"56","author":"Fujiwara","year":"2015","journal-title":"J\u00a0Radiat Res"},{"key":"10.1016\/j.esmoop.2022.100565_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jso.22052","article-title":"The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer","volume":"105","author":"Yin","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2009.09.002","article-title":"Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors","volume":"115","author":"Mabuchi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1525-1438.2007.01141.x","article-title":"Phase I study of weekly nedaplatin and concurrent pelvic radiotherapy as adjuvant therapy after radical surgery for cervical cancer","volume":"18","author":"Kodama","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.esmoop.2022.100565_bib20","first-page":"1551","article-title":"A\u00a0phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study","volume":"19","author":"Yokoyama","year":"2008","journal-title":"Oncol Rep"},{"key":"10.1016\/j.esmoop.2022.100565_bib21","doi-asserted-by":"crossref","first-page":"762366","DOI":"10.3389\/fonc.2021.762366","article-title":"Hematological toxicities of concurrent chemoradiotherapies in head and neck cancers: comparison among cisplatin, nedaplatin, lobaplatin, and nimotuzumab","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000273207","article-title":"Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone","volume":"69","author":"Mabuchi","year":"2010","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.esmoop.2022.100565_bib23","first-page":"6983","article-title":"Phase II study of concurrent chemoradiotheapy using nedaplatin for locally advanced uterine cervical carcinoma (KGROG0501): final results","volume":"37","author":"Niibe","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2022.100565_bib24","first-page":"763","article-title":"[Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix]","volume":"48","author":"Li","year":"2013","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/j.esmoop.2022.100565_bib25","first-page":"517","article-title":"Initial analysis of relationship between plasma platinum concentration and hematological adverse reaction associated with weekly chemotherapy using nedaplatin in combination with radiotherapy for cervical carcinoma","volume":"31","author":"Hamada","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.esmoop.2022.100565_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543784.2016.1116517","article-title":"Targeting angiogenesis in endometrial cancer-new agents for tailored treatments","volume":"25","author":"Papa","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.esmoop.2022.100565_bib27","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1002\/jcp.29440","article-title":"Targeting cervical cancer: is there a role for poly (ADP-ribose) polymerase inhibition?","volume":"235","author":"Tomao","year":"2020","journal-title":"J\u00a0Cell Physiol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:12Z","timestamp":1761856152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2059702922001934"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100565","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100565"}}